ClinicalTrials.gov
public full text
Public Domain
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Graz Study on the Risk of Atrial Fibrillation#1151117
- Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling#1152653
- AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke#858618
- Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke#1164675
- The Effect of Nurse Practitioner Led-Care on Quality of Life in Patients With Atrial Fibrillation#1163956
Record · ID 1230662
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive